Category Archives: Growth Hormone Secretagogues

Insulin-like Growth Factor-1 Long R3 (IGF-1 LR3) is a synthetic 83-amino-acid recombinant peptide analogue of native human IGF-1. Engineered with an amino acid substitution (arginine for glutamic acid at position 3) plus an additional 13-amino-acid N-terminal extension peptide, IGF-1 LR3 is approximately three times more potent than native IGF-1 in cellular proliferation assays.

MK 677, also known chemically as Ibutamoren mesylate, is a non-peptide, orally active growth hormone secretagogue that functions as a potent agonist at the ghrelin (GHS-R1a) receptor. Unlike injectable peptides that require reconstitution and cold-chain shipping, MK 677 is a small molecule that retains stability at room temperature and exhibits high oral bioavailability in laboratory models.

Finding authentic Tesamorelin for sale online requires diligent chemical verification. Because Tesamorelin is a large 44-amino-acid chain that requires specialized organic synthesis to conjugate the trans-3-hexenoyl group at the N-terminus, it is one of the most expensive and difficult peptides to manufacture.

Tesamorelin is a synthetic 44-amino-acid peptide analogue of human Growth Hormone Releasing Hormone (GHRH), modified with a trans-3-hexenoyl fatty acid moiety at its N-terminal tyrosine. This structural modification endows Tesamorelin with unprecedented enzymatic stability, rendering it the most potent GHRH analogue currently available for research.

Evaluating Sermorelin for sale in research chemical marketplaces requires careful inspection of synthesis purity and C-terminal amidation. Sermorelin’s terminal residue is amidated (Arg-NH2); synthesis without this terminal amide modification diminishes its binding affinity to the pituitary GHRH receptor by more than 80%.

Sermorelin represents the shortest functional fragment of native Growth Hormone Releasing Hormone that retains full biological activity. Consisting of the first 29 amino acids of human GHRH (GHRH 1-29 amide), Sermorelin serves as a foundational compound for investigating pituitary somatotrope function and natural feedback loops.

The combination of CJC 1295 (No DAC) and Ipamorelin is one of the most widely investigated synergistic peptide protocols in endocrine physiology. By simultaneously activating two separate, non-competing receptor pathways on anterior pituitary somatotropes, this co-formulation produces growth hormone release that is significantly greater than the sum of either peptide administered alone.

CJC 1295 is a synthetic 30-amino-acid tetrasubstituted peptide analogue of Growth Hormone Releasing Hormone (GHRH 1-29). By replacing four key amino acids within the native sequence, CJC 1295 dramatically resists enzymatic degradation by dipeptidyl peptidase-4 (DPP-4).

Evaluating Ipamorelin for sale requires confirming synthesis authenticity, particularly the presence of unnatural amino acids within its sequence. Ipamorelin contains two non-standard residues—aminoisobutyric acid (Aib) at position 1 and D-2-naphthylalanine (D-2-Nal) at position 3—plus a C-terminal amide cap.

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, belonging to the growth hormone secretagogue (GHS) family. Unlike older peptide secretagogues (such as GHRP-2 or GHRP-6), Ipamorelin is distinguished by its extraordinary receptor selectivity.